Loading...
XNYS
TFX
Market cap5.14bUSD
Jul 11, Last price  
116.40USD
1D
-2.95%
1Q
-10.39%
Jan 2017
-27.77%
Name

Teleflex Inc

Chart & Performance

D1W1MN
No data to show
P/E
73.82
P/S
1.69
EPS
1.58
Div Yield, %
0.88%
Shrs. gr., 5y
Rev. gr., 5y
3.26%
Revenues
3.05b
+2.45%
2,514,552,0002,646,757,0001,934,332,0002,420,949,0001,890,062,0001,801,705,0001,528,911,0001,551,009,0001,696,271,0001,839,832,0001,809,690,0001,868,027,0002,146,303,0002,448,383,0002,595,362,0002,537,156,0002,809,563,0002,791,041,0002,974,489,0003,047,324,000
Net income
70m
-80.45%
138,817,000139,430,000146,484,000119,774,000302,994,000201,094,000323,329,000-190,057,000150,881,000187,679,000244,863,000237,377,000152,530,000200,802,000461,466,000335,324,000485,374,000363,139,000356,328,00069,675,000
CFO
636m
+24.50%
335,892,000344,662,000393,588,000171,169,000204,171,000213,102,00094,478,000186,054,000226,544,000286,565,000300,810,000408,480,000419,885,000437,378,000439,525,000436,406,000651,419,000342,141,000510,638,000635,739,000
Dividend
Aug 15, 20240.34 USD/sh
Earnings
Jul 30, 2025

Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
IPO date
Mar 17, 1980
Employees
15,500
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,047,324
2.45%
2,974,489
6.57%
2,791,041
-0.66%
Cost of revenue
1,506,317
1,481,909
1,413,773
Unusual Expense (Income)
NOPBT
1,541,007
1,492,580
1,377,268
NOPBT Margin
50.57%
50.18%
49.35%
Operating Taxes
5,316
76,440
83,003
Tax Rate
0.34%
5.12%
6.03%
NOPAT
1,535,691
1,416,140
1,294,265
Net income
69,675
-80.45%
356,328
-1.88%
363,139
-25.18%
Dividends
(63,541)
(63,896)
(63,789)
Dividend yield
0.76%
0.54%
0.54%
Proceeds from repurchase of equity
(200,000)
BB yield
2.39%
Debt
Debt current
100,000
87,500
87,500
Long-term debt
1,754,179
1,950,172
1,864,897
Deferred revenue
Other long-term liabilities
124,323
189,861
191,257
Net debt
1,563,991
1,814,824
1,648,451
Cash flow
Cash from operating activities
635,739
510,638
342,141
CAPEX
(126,434)
(91,442)
(79,190)
Cash from investing activities
(99,358)
(621,228)
(257,941)
Cash from financing activities
(421,925)
38,540
(217,506)
FCF
1,561,233
1,302,789
1,079,197
Balance
Cash
290,188
222,848
292,034
Long term investments
11,912
Excess cash
137,822
74,124
164,394
Stockholders' equity
3,847,297
3,843,377
3,461,739
Invested Capital
6,019,666
6,483,097
5,856,055
ROIC
24.57%
22.95%
22.73%
ROCE
23.53%
21.28%
21.49%
EV
Common stock shares outstanding
47,094
47,304
47,309
Price
177.98
-28.62%
249.34
-0.12%
249.63
-24.00%
Market cap
8,381,790
-28.94%
11,794,779
-0.13%
11,809,746
-24.19%
EV
9,945,781
13,609,603
13,458,197
EBITDA
1,815,608
1,734,698
1,607,858
EV/EBITDA
5.48
7.85
8.37
Interest
83,544
85,082
54,264
Interest/NOPBT
5.42%
5.70%
3.94%